Skip to main content
Figure 3 | BMC Musculoskeletal Disorders

Figure 3

From: Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

Figure 3

Proportion of patients with LDAS or remission at baseline and at month 6. (A) Assessed by the DAS28 (ESR), (B) by the DAS28 (CRP), and (C) by the CDAI. LDAS was defined as a DAS28 score ≤3.2 or a CDAI score ≤10. Remission was defined as a DAS28 score <2.6 or a CDAI score ≤2.8. Error bars represent 95% CI. *Includes patients receiving abatacept as a second- or further-line of treatment. CDAI, Clinical Disease Activity Index; CI, confidence interval; CRP, C-reactive protein; DAS28, 28-item Disease Activity Score; ESR, erythrocyte sedimentation rate; LDAS, low disease activity state.

Back to article page